

ORAL PRESENTATION

Open Access

Beyond insulin: rethinking cellular metabolism

Craig B Thompson

From Metabolism, diet and disease
Washington, DC, USA. 29-31 May 2012

The latest cancer therapeutics are almost all inhibitors of oncogenes or their downstream mediators. With the exception of imatinib, most such drugs have been disappointing in the clinic. In contrast, existing successful cancer drugs have a therapeutic index because they render the consequences of oncogene activation selectively toxic to the cancer cell. A renewed focus on this type of approach appears warranted and should be considered.

Published: 1 June 2012

doi:10.1186/1753-6561-6-S3-O25

Cite this article as: Thompson: Beyond insulin: rethinking cellular metabolism. *BMC Proceedings* 2012 **6**(Suppl 3):O25.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA



© 2012 Thompson; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.